Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?
Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC. Curr Opin Urol. 2012 Nov 15. [Epub ahead of print]

Source

aDepartment of Urology, New York University, New York, New York bBrady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Abstract

PURPOSE OF REVIEW:

To determine whether alpha-blockers, commonly used for the treatment of benign prostatic hyperplasia, are associated with prostate cancer risk.

RECENT FINDINGS:

Alpha-blockers have been associated with a reduced risk of prostate cancer aggressiveness in some observational studies and an increased risk in other studies. However, this relationship is complex as different alpha-blockers have divergent effects in laboratory studies and there are many confounders in daily practice such as differential screening practices.

SUMMARY:

Both benign prostatic hyperplasia and prostate cancer are common conditions in the aging male population, such that an interaction between alpha-blockers and prostate cancer risk is clinically relevant. Prospective evidence is necessary to establish a definitive link.